Success Metrics

Clinical Success Rate

89.7%

Based on 26 completed trials

Completion Rate

90%(26/29)

Active Trials

3(9%)

Results Posted

77%(20 trials)

Terminated

3(9%)

Phase Distribution

Ph phase_1

Ph phase_3

33%

Ph phase_4

18%

Ph not_applicable

15%

Ph phase_2

15%

Ph early_phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution33 total trials

Early Phase 1First-in-human

3(9.1%)

Phase 1Safety & dosage

3(9.1%)

Phase 2Efficacy & side effects

5(15.2%)

Phase 3Large-scale testing

11(33.3%)

Phase 4Post-market surveillance

6(18.2%)

N/ANon-phased studies

5(15.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.7%

26 of 29 finished

Non-Completion Rate

10.3%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(26)

Terminated(3)

Other(1)

Detailed Status

Completed26

Terminated3

Active, not recruiting2

Recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

89.7%

Most Advanced

Phase 4

Trials by Phase

Early Phase 13 (9.1%)

Phase 13 (9.1%)

Phase 25 (15.2%)

Phase 311 (33.3%)

Phase 46 (18.2%)

N/A5 (15.2%)

Trials by Status

recruiting13%

active_not_recruiting26%

terminated39%

unknown13%

completed2679%

Recent Activity

3 active trials

Showing 5 of 33

active_not_recruitingphase_2

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

NCT04539808

completedphase_4

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)

NCT04106856

View all 33 trials

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more

NCT04539808Phase 2

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Active Not Recruiting

NCT05402397Phase 4

Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies

Completed

NCT04632589Early Phase 1

Losartan for Improved Vascular Endothelial Function After Preeclampsia

Completed

NCT06636812Early Phase 1

Losartan and Emotional Processing in Young People

Recruiting

NCT04106856Phase 1

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)

Active Not Recruiting

NCT00429364Phase 3

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

Completed

NCT00140907Phase 4

ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)

Completed

NCT00756938Phase 3

Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)

Completed

NCT00447603Phase 3

A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)

Terminated

NCT00568178Phase 3

An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

Completed

NCT00496834Phase 4

LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

Completed

NCT05828940Not Applicable

Losartan and Memory

Completed

NCT00953680Phase 1

Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)

Completed

NCT00943852Phase 1

The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)

Completed

NCT05132712Early Phase 1

Effects of Angiotensin Converting Enzyme Inhibitors on Patency of Arterio-Venous Fistulas: A Randomized Controlled Trial

Unknown

NCT03467217Phase 2

Losartan for the Treatment of Pediatric NAFLD

Terminated

NCT01808196Phase 2

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

Completed

NCT03029091Phase 2

An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)

Completed

NCT04222686Phase 4

Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients

Completed

NCT01302691Phase 3

MK-0954E Study in Participants With Hypertension (MK-0954E-357)

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 33